These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36384532)

  • 21. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
    Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
    Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2.
    Chun JY; Jeong H; Kim Y
    JAMA Netw Open; 2022 Mar; 5(3):e223064. PubMed ID: 35302625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination Prioritization Strategies for COVID-19 in Korea: A Mathematical Modeling Approach.
    Choi Y; Kim JS; Kim JE; Choi H; Lee CH
    Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33923600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universal screening for SARS-CoV-2 infection: a rapid review.
    Viswanathan M; Kahwati L; Jahn B; Giger K; Dobrescu AI; Hill C; Klerings I; Meixner J; Persad E; Teufer B; Gartlehner G
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013718. PubMed ID: 33502003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the impact of reopening schools in the UK in early 2021 in the presence of the alpha variant and with roll-out of vaccination against SARS-CoV-2.
    Panovska-Griffiths J; Stuart RM; Kerr CC; Rosenfield K; Mistry D; Waites W; Klein DJ; Bonell C; Viner RM
    J Math Anal Appl; 2022 Oct; 514(2):126050. PubMed ID: 35153332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study.
    Russell TW; Wu JT; Clifford S; Edmunds WJ; Kucharski AJ; Jit M;
    Lancet Public Health; 2021 Jan; 6(1):e12-e20. PubMed ID: 33301722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons drawn from Shanghai for controlling highly transmissible SARS-CoV-2 variants: insights from a modelling study.
    Wang H; Li T; Gao H; Huang C; Tang B; Tang S; Cheke RA; Zhou W
    BMC Infect Dis; 2023 May; 23(1):331. PubMed ID: 37194011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.
    Yi S; Kim JM; Choe YJ; Hong S; Choi S; Ahn SB; Kim M; Park YJ
    J Korean Med Sci; 2022 Jan; 37(1):e12. PubMed ID: 34981682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529).
    Chun JY; Jeong H; Kim Y
    BMC Med; 2022 Nov; 20(1):451. PubMed ID: 36419108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study.
    Leung K; Wu JT; Leung GM
    Lancet Public Health; 2021 Sep; 6(9):e674-e682. PubMed ID: 34388389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
    Mancuso M; Eikenberry SE; Gumel AB
    Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S
    Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to COVID-19 in South Korea and implications for lifting stringent interventions.
    Dighe A; Cattarino L; Cuomo-Dannenburg G; Skarp J; Imai N; Bhatia S; Gaythorpe KAM; Ainslie KEC; Baguelin M; Bhatt S; Boonyasiri A; Brazeau NF; Cooper LV; Coupland H; Cucunuba Z; Dorigatti I; Eales OD; van Elsland SL; FitzJohn RG; Green WD; Haw DJ; Hinsley W; Knock E; Laydon DJ; Mellan T; Mishra S; Nedjati-Gilani G; Nouvellet P; Pons-Salort M; Thompson HA; Unwin HJT; Verity R; Vollmer MAC; Walters CE; Watson OJ; Whittaker C; Whittles LK; Ghani AC; Donnelly CA; Ferguson NM; Riley S
    BMC Med; 2020 Oct; 18(1):321. PubMed ID: 33032601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of COVID-19 Management Policies Tailored to Airborne SARS-CoV-2 Transmission: Policy Analysis.
    Telles CR; Roy A; Ajmal MR; Mustafa SK; Ahmad MA; de la Serna JM; Frigo EP; Rosales MH
    JMIR Public Health Surveill; 2021 Apr; 7(4):e20699. PubMed ID: 33729168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.